Keywords: dor, biopharma, starts, orbec, npap, asean, region

DOR BioPharma starts orBEC NPAP for ASEAN region

Article | 01 September 2008

DOR BioPharma, a late-stage, US biopharmaceutical company developing products to treat the life-threatening side effects of cancer therapies and serious ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Nystatin

Go to drug listing